Clinical Trial Update: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of COM902, a TIGIT inhibitor, in patients with advanced malignancies is ongoing and currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma
• Lung Cancer
• Multiple Myeloma
• Ovarian Cancer
• Plasma Cell Neoplasm

Drugs mentioned

• COM902

Snippet

Sponsor: Compugen Ltd | Conditions: Advanced Cancer, Ovarian Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING